NDAORALTABLET, EXTENDED RELEASEPriority Review
Approved
Feb 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Mechanism of Action
(DM) is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist. Quinidine increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan. The mechanism by which dextromethorphan…
Indications (1)
Clinical Trials (2)
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Started Oct 2017
601 enrolled
Agitation in Patients With Dementia of the Alzheimer's Type
Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female Volunteers
Started Nov 2007
42 enrolled
Healthy